Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States

OBJECTIVES: The aim was to evaluate the cost-effectiveness of niraparib compared with routine surveillance (RS), olaparib and rucaparib for the maintenance treatment of patients with recurrent ovarian cancer (OC). METHODS: A decision-analytic model estimated the cost per quality-adjusted life-year (...

Descripción completa

Detalles Bibliográficos
Autores principales: Guy, Holly, Walder, Lydia, Fisher, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386009/
https://www.ncbi.nlm.nih.gov/pubmed/30478649
http://dx.doi.org/10.1007/s40273-018-0745-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386009/
https://www.ncbi.nlm.nih.gov/pubmed/30478649
http://dx.doi.org/10.1007/s40273-018-0745-z

Ejemplares similares